For Immediate Release
Chief Marketing Officer
SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER
Biotech Veteran Joins the Mission to Cure Rare Cancer
CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced it has appointed Johanne Kaplan, PhD, to the position of Chief Scientific Officer. In this role, Dr. Kaplan will oversee and support SHEPHERD’s scientific programs. “The appointment of Dr. Kaplan is an exciting addition to the SHEPHERD team,” said CEO and founder David Hysong. “Dr. Kaplan brings an impressive skill set and wealth of experience to SHEPHERD and will substantively contribute to the planning and development of our project portfolio.”
“I am very excited to be joining the dynamic team at SHEPHERD and I look forward to helping execute on the inspiring mission of developing cures for rare cancers,” said Dr. Kaplan.
About Dr. Johanne Kaplan
Prior to Shepherd, Dr. Kaplan spent 24 years at Genzyme, most recently serving as Vice President of Research. In this position, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. Dr. Kaplan also led Genzyme’s successful development of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. Her work has resulted in over 60 scientific publications and multiple patents. Dr. Kaplan holds a B.Sc. and a Ph.D. in Microbiology and Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.
About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.